首页> 美国卫生研究院文献>Elsevier Sponsored Documents >Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial–Based Cost Data

【2h】

Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial–Based Cost Data

机译：通过在ADDITION-UK试验中进行筛查发现的2型糖尿病患者的强化治疗的增量费用和成本效益：基于经验试验的费用数据的更新

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThere is uncertainty about the cost effectiveness of early intensive treatment versus routine care in individuals with type 2 diabetes detected by screening.

机译：背景通过筛查发现，对于2型糖尿病患者而言，早期强化治疗与常规治疗的成本效果尚不确定。

著录项

期刊名称 Elsevier Sponsored Documents
作者
Michael Laxy; Edward C.F. Wilson; Clare E. Boothby; Simon J. Griffin;
展开▼
作者单位

展开▼
年(卷),期 -1(20),10
年度 -1
页码 1288–1298
总页数 11
原文格式 PDF
正文语种
中图分类
关键词
ADDITION trial cost effectiveness intensive treatment screen-detected diabetes;

机译：ADDITION试验;成本效益;强化治疗;经筛查的糖尿病;

相似文献

外文文献
中文文献
专利

1. Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial–Based Cost Data [J] . Michael Laxy, Edward C.F. Wilson, Clare E. Boothby, Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第10期

机译：通过筛选术语检测的2型糖尿病患者的增量成本和成本效益：筛选 - 英国试验中的型号：与基于经验试验的成本数据的更新
2. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial [J] . Tao L., Wilson E. C. F., Wareham N. J., Diabetic medicine: A journal of the British Diabetic Association . 2015,第7期

机译：与筛查发现的2型糖尿病患者进行常规综合治疗相比，强化多因素治疗的成本效益：ADDITION-UK整群随机对照试验的分析
3. A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluationsFelix Achana, Stavros Petrou, Kamran Khan, Amadou Gaye, Neena Modi, On behalf of Medicines for Neonates Investigators [J] . The European journal of health economics: HEPAC : health economics in prevention and care . 2018,第1期

机译：用于评估成本效益结果之间的协议的方法框架，估计有关审判的经济评估的替代数据的替代数据来源和审判的经济评估效果，斯塔夫罗斯·佩特鲁，Kamran汗，Neena Modi，代表新生儿调查人员的药物
4. Minimizing the Costs of Screening Trials [C] . Quentin F. Stout, Janis Hardwick Symposium on the interface . 1999

机译：最大限度地减少筛选试验的费用
5. Reduced costs of trisomy 21 from integrated screening: Are they sufficient to justify early screening in the United States? A benefit-cost analysis using FASTER trial data [D] . Persutte, Wayne H. 2006

机译：通过综合筛查降低了21三体性疾病的成本：它们是否足以证明在美国进行早期筛查的合理性？使用FASTER试验数据进行收益成本分析
6. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial [O] . L Tao, E C F Wilson, N J Wareham, -1

机译：与筛查发现的2型糖尿病患者进行常规综合治疗相比强化多因素治疗的成本效益：ADDITION-UK整群随机对照试验的分析
7. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial [O] . Tao, L., Wilson, E. C., Wareham, N. J., 2015

机译：与筛查发现的2型糖尿病患者进行常规综合治疗相比，强化多因素治疗的成本效益：ADDITION-UK整群随机对照试验的分析

Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial–Based Cost Data

摘要

著录项

相似文献

相关主题

期刊订阅